Targets › OSPAB
1 program from 1 company in 9 trials: 5 Phase 3, 4 Phase 1; Infectious disease, Metabolic and endocrine, Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on OSPAB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | CMP 001 6-valent OspA-based Lyme disease vaccine | ESR1, OSPAB | Phase 3 | Lyme Disease; Advanced Malignancies; Lyme Borreliosis; Advanced Breast Cancer … | Dec 2026 |
Breast Cancer (2) Lyme Disease (1) Advanced Malignancies (1) Lyme Borreliosis (1) Advanced Breast Cancer (1) Pneumococcal Diseases (1) Obesity and Obesity-related Medical Conditions (1) Pneumococcal Disease (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.